Why Tempus AI, Inc. (TEM) Stock Fell 13.8% on Oct 6, 2026
The clearest new catalyst: High-beta profit-taking reversal (no fresh adverse news).
Why did TEM stock fall?
Tempus AI fell 13.85% to $71.98 on Tuesday, October 6, 2026 (from $83.55), a sharp high-beta reversal that largely reversed the prior day's ~9% gain, amid weakness in several high-momentum healthcare/genomics names. There was no fresh adverse Tempus catalyst — in fact the day's merger news was positive (the Personalis antitrust waiting period had expired and BTIG expected the deal to close at terms with no higher bid) — and the broad market rose to records, so the drop reads as profit-taking in an extended growth stock rather than a reaction to new bad news.
- High-beta profit-taking reversal (no fresh adverse news): TEM fell 13.85% on about 16.4-16.6 million shares (versus 7.3 million the prior day), largely giving back Monday's ~9% jump. No negative Tempus earnings warning, FDA setback, reimbursement loss or guidance cut landed on October 6; the move was a sharp unwind in a volatile, high-valuation name, part of broad weakness in high-momentum healthcare/genomics stocks that day.
- The day's Personalis merger news was positive, not negative: The ~$1.7 billion ($1.5 billion net) acquisition of Personalis at $16.25/share was announced back on July 20, 2026 — it is an old catalyst. The fresh October 6 developments actually reduced deal risk: Personalis disclosed that the Hart-Scott-Rodino antitrust waiting period had expired (October 2), removing a closing condition, and BTIG downgraded Personalis to Neutral specifically because it had grown more confident the Tempus deal would close at the agreed terms, explicitly not expecting a higher competing bid.
- Dilution overhang and valuation (standing concerns, not new): Because the Personalis deal is structured principally in stock (Tempus may elect up to 50% cash), potential dilution is a legitimate overhang — and greater confidence that the deal will close may have refocused investors on it. But that is interpretation, not a proven cause, and it is not new information. Tempus actually posted positive GAAP net income (~$5.6 million) and adjusted EBITDA (~$8.0 million) last quarter with full-year adjusted EBITDA guidance around $65 million, so this was valuation/profit-taking, not fresh profitability deterioration.
How the story developed
- July 20, 2026Tempus announces the acquisition of Personalis at $16.25/share (~$1.7B total, ~$1.5B net), structured largely in stock (background).
- October 2, 2026The Hart-Scott-Rodino antitrust waiting period for the Personalis deal expires, removing a closing condition (disclosed October 6).
- October 6, 2026TEM falls 13.85% to $71.98, largely reversing Monday's ~9% jump, on profit-taking amid weak high-momentum healthcare names — even as the broad market hits records and BTIG signals deal confidence.
What it could mean for TEM investors
The constructive case
- The day's Personalis merger news was favorable — antitrust clearance and analyst confidence in a close at agreed terms — not a new negative.
- Tempus posted positive GAAP net income and adjusted EBITDA last quarter, so the drop was valuation/profit-taking, not a fundamental deterioration.
The cautious case & what could invalidate it
- As a high-valuation, high-beta growth stock, TEM is prone to sharp reversals like this one.
- The Personalis deal's largely-stock structure leaves a potential dilution overhang as it moves toward close.
- A continued de-rating of the high-momentum healthcare/genomics trade could keep pressure on the stock.
Initial detection
BestStocks first flagged TEM intraday on Oct 6, 2026; this analysis was finalized after the close using the confirmed −15.3% session move and additional catalyst research.
Show the initial intraday note
Tempus AI, Inc. (TEM) fell 13.85% to close at $71.98 on Tuesday, October 6, 2026 (from $83.55), a sharp high-beta reversal that largely gave back the prior day's ~9% jump, amid broad weakness in high-momentum healthcare and genomics names. Notably, the day's actual Tempus-related news was positive, not negative: the antitrust waiting period for its Personalis acquisition had expired (removing a closing condition), and BTIG said it expected that deal to close at the agreed terms with no higher competing bid. With no fresh adverse company catalyst and the broad market at record highs, the drop reads as profit-taking in an extended, volatile growth stock.
What to watch next: The move was a positioning/valuation reset, not a reaction to bad operating news, so watch whether the high-momentum healthcare/genomics group keeps de-rating and whether Tempus's growth and improving profitability (it posted positive GAAP net income and adjusted EBITDA last quarter) hold up at its next report. The Personalis acquisition — roughly $1.5 billion net, structured largely in stock — remains a potential dilution overhang to watch as it moves toward close.
Frequently asked questions
Why did Tempus AI, Inc. (TEM) stock fall on Oct 6, 2026?
Tempus AI fell 13.85% to $71.98 on Tuesday, October 6, 2026 (from $83.55), a sharp high-beta reversal that largely reversed the prior day's ~9% gain, amid weakness in several high-momentum healthcare/genomics names. There was no fresh adverse Tempus catalyst — in fact the day's merger news was positive (the Personalis antitrust waiting period had expired and BTIG expected the deal to close at terms with no higher bid) — and the broad market rose to records, so the drop reads as profit-taking in an extended growth stock rather than a reaction to new bad news.
How much did TEM stock fall on Oct 6, 2026?
TEM fell 15.3% during the Oct 6, 2026 trading session.
What were the main drivers behind TEM's move?
High-beta profit-taking reversal (no fresh adverse news); The day's Personalis merger news was positive, not negative; Dilution overhang and valuation (standing concerns, not new).